Pfizer (NYSE:PFE) Shares Climb 1.6% on Analyst Upgrade

Pfizer Inc. (NYSE:PFE)’s stock price was up 1.6% on Friday after JPMorgan Chase & Co. raised their price target on the stock from $28.00 to $30.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. Pfizer traded as high as $28.29 and last traded at $28.2710. 22,597,865 shares changed hands during trading, a decline of 44% from the average session volume of 40,465,797 shares. The stock had previously closed at $27.82.

PFE has been the subject of several other reports. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Guggenheim lowered their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. HSBC lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Finally, Scotiabank increased their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.72.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for patients with HER2-positive metastatic breast cancer. The expanded label moves TUKYSA into an earlier stage of care, potentially broadening its addressable market and supporting Pfizer’s oncology-growth strategy. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Jefferies initiated or reiterated a Buy rating on Pfizer, while Cantor Fitzgerald raised its price target to $28, providing additional support for the stock’s valuation narrative. A separate analysis also upgraded Pfizer to a cautious bullish view. Pfizer Receives a Buy from Jefferies
• Positive Sentiment: Investors continue to view Pfizer as a potential value play because of its low forward earnings multiple, substantial cash-generation capacity and dividend yield. The company’s oncology pipeline, including TUKYSA and the advancing Phase 3 tilrekimig asthma program, may help offset pressure from slower legacy-product growth. Pfizer’s Tilrekimig Phase 3 Trial
• Neutral Sentiment: Pfizer’s next earnings report is a key catalyst. Analysts expect oncology sales, biosimilars, pipeline progress and the company’s ability to deliver another earnings beat to determine whether the valuation discount is justified.
• Negative Sentiment: Pfizer’s dividend yield above 6% is drawing scrutiny because it may reflect a depressed share price and investor concerns about earnings, cash flow, debt and payout sustainability. Commentators warn that a frozen dividend and prior write-downs make the high yield less reassuring than it appears. Pfizer’s Dividend Yield Is Above 6%
• Negative Sentiment: Pfizer plans to close a penicillin unit in Italy and eliminate approximately 330 jobs. The restructuring could improve efficiency, but it also highlights ongoing pressure to reduce costs amid sluggish revenue growth, thin margins and concerns about returns on equity.

Institutional Trading of Pfizer

A number of large investors have recently bought and sold shares of PFE. Riversedge Advisors LLC lifted its stake in shares of Pfizer by 153.1% in the 3rd quarter. Riversedge Advisors LLC now owns 28,400 shares of the biopharmaceutical company’s stock valued at $810,000 after purchasing an additional 17,180 shares during the period. Wedmont Private Capital grew its stake in Pfizer by 138.1% during the third quarter. Wedmont Private Capital now owns 99,498 shares of the biopharmaceutical company’s stock worth $2,768,000 after purchasing an additional 57,713 shares during the period. Werlinich Asset Management LLC grew its stake in Pfizer by 0.4% during the third quarter. Werlinich Asset Management LLC now owns 92,600 shares of the biopharmaceutical company’s stock worth $2,641,000 after purchasing an additional 400 shares during the period. Journey Retirement Planning & Investment Management LLC bought a new stake in Pfizer in the third quarter worth approximately $222,000. Finally, WoodTrust Financial Corp lifted its stake in Pfizer by 0.3% in the third quarter. WoodTrust Financial Corp now owns 418,180 shares of the biopharmaceutical company’s stock valued at $11,927,000 after buying an additional 1,294 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

The stock has a market capitalization of $161.14 billion, a price-to-earnings ratio of 37.20, a price-to-earnings-growth ratio of 1.88 and a beta of 0.32. The company has a 50 day simple moving average of $27.62 and a 200-day simple moving average of $26.49. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.